Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Research and Innovation Action · Running

KeratOPrinter Advanced 4D Printing Technologies in Corneal Regeneration: A Pathway to Restored Vision

Coordinator
Tampereen Korkeakoulusaatio Sr, Finland
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
10 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101191726

What the project is doing

In the project's own words, from its summary on CORDIS.

Corneal blindness is the 3rd leading cause of blindness globally, affecting >11.7mi people. Although the cornea is the most transplanted tissue, only 1-in-70 patients in need receive a cornea due to a severe shortage of donor tissue.3D bioprinting offers an attractive solution. However, existing technology cannot mimic the complexity of cornea tissue, which is necessary to reproduce its optomechanical & biological functionality.

The KeratOPrinter project thus, proposes a highly ambitious approach to develop a 4D bioprinting suite that can deliver a fully functional, biocompatible, full-thickness native-like human cornea. The consortium combines world-class partners to provide:a) An innovative & scalable cell source with high cell viability & native-like functionality in vivo for the different cell types in the cornea; b) Several multi-material bioink formulations which can reproduce the native-environment heterogeneity & extracellular matrix to deliver the optical, mechanical & biological functionality; c) Single-cell bioprinting resolution with µm accuracy & in-process monitoring for clinical-level quality control at viable printing speeds; d) Clinical handling technology for transportation, logistics & surgical implementation, supported by complementary implementation of multiple bioprinting technologies; e) GMP-compliant cell manufacturing and bioprinting technologies supported by in vivo & GLP studies for fast translation to the clinical environment; f) Early regulatory engagement augmented by a thorough regulatory and ethical analysis culminating in a comprehensive regulatory pathway to support future commercialisation and g) A dedicated community of researchers, clinicians, healthcare providers, regulatory and standardisation bodies, patient groups, technology developers, & industry to translate project results into targeted outcomes & long-term impacts.

Ultimately, KeratOPrinter aims to enable millions of people to receive vision-saving therapy by 2035.

Topics

Who is involved

OrganisationCityCountryRole
Tampereen Korkeakoulusaatio SrTampereFinlandCoordinator
Cellbox SolutionsKolnGermanyParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Asphalion SLBarcelonaSpainParticipant
Brinter OyTurkuFinlandParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Stemsight OyTampereFinlandParticipant
Crowdhelix LimitedCorkIrelandParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI